References: Hair growth and hair loss
Cancer Chemother Pharmacol. 1991;27(5):389-93.
Carboplatin/etoposide as first-line chemotherapy in advanced ovarian carcinoma: a pilot study.
Eiermann W, Achterrath W, Lenaz L, Hepp H.
Klinikum Grosshadern der Universitat, Munchen, Federal Republic of Germany.
In a pilot study, 18 patients with advanced ovarian cancer were evaluated for tolerance and response to a combination treatment with a fixed dose of carboplatin (350 mg/m2 given i.v. on day 1) and escalated doses of etoposide (70-130 mg/m2 daily given i.v. on days 1-3) as first-line chemotherapy. The maximum tolerated dose of etoposide was 130 mg/m2 when given i.v. on days 1-3 in combination with 350 mg/m2 carboplatin given i.v. every 4 weeks. At these dose levels, bone marrow toxicity was manageable and did not appear to be cumulative. In all, 12 objective responses, including 9 complete responses (CRs) and 3 partial responses (PRs), were achieved in 18 patients; 6 of the 9 CRs were confirmed as pathological CRs by second-look surgery.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1998999&dopt=Abstract
J Am Acad Dermatol. 1991 Feb;24(2 Pt 1):227-30.
Prognostic factors in the treatment of alopecia areata with diphenylcyclopropenone.
van der Steen PH, van Baar HM, Happle R, Boezeman JB, Perret CM.
Department of Dermatology, University of Nijmegen, The Netherlands.
One hundred thirty-nine patients with alopecia areata were treated with diphenylcyclopropenone. Before treatment, 85 patients had subtotal or total hair loss (greater than 90% bald area) and in the remaining patients scalp involvement was between 40% and 90%. The following three factors were found to be of prognostic significance: type of alopecia areata as documented before treatment, duration of the disease before therapy, and presence of nail changes. Other factors such as age at onset, sex, presence of atopic features, the extent of variation in the range of diphenylcyclopropenone concentrations during treatment, and sleep disturbances caused by pruritus did not influence the prognosis significantly.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2007667&dopt=Abstract
Hautarzt. 1977 Dec;28(12):619-25.
[Hormones and hair growth in man]
[Article in German]
Moretti G, Rampini E, Rebora A.
A literature review tries to diminish the ambiguity between hormones and hairs. Therefore the hormonal action in general (regulation of the protein synthesis indirectly by enzymatical regulation of the AMP-system or directly by hormones as active metabolites) and the methods to explore hormones-hair-interaction are discussed. Hormones pertaining to the pituitary-adrenal-gonadal axis are regarded as the paramount hormones; therefore the results of research in testosterone, 5-alpha-dihydrotestosterone, estrogens, progesterone, glucocorticoids, the hypophysis and its tropins are recapitulated. The main disorders of hair-growth, pattern baldness and "idiopathic" hirsutism, which would be dependent on a similar disturbance of androgen metabolism, are discussed. Pathology in hair-growth may arise in any point of the cascade of hormone action.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=202580&dopt=Abstract
Natural Herbal Supplements ||
Hair Million herbal formula for hair loss and hair growth ||
Hair growth research references ||
Online Pharmacy : discount prescription medication ||